Navigation Links
New Botox(R) Alternative Dysport(TM) FDA Approved, Ready to Rumble
Date:4/30/2009

NORTH DALLAS, Texas and PLANO, Texas, April 30 /PRNewswire/ -- The battle for beauty now goes wrinkle-to-wrinkle, as Botox's rival, Dysport(TM), has received FDA clearance and is expected to begin their challenge to Botox(R) sometime within the next sixty days. The arrival of Dysport(TM) into the U.S. aesthetics market is sure to spark heated competition not only between the two wrinkle treatments; but also between medical professionals soon to be promoting one over the other, and as alternate wrinkle reducing options within the same medical spa. Medicis, a U.S. aesthetics giant (known for their popular Restylane(R) and Perlane(R) facial fillers) will promote the Dysport(TM) brand as part of a U.S. sales agreement with the manufacturer, Ipsen. Adding Dysport(TM) to their dermal filler empire positions Medicis as a formidable foe to Allergan and their arsenal of beauty treatments (Botox(R) and the Juvederm(R) hyaluronic acid gel fillers).

Botox(R) by Allergan, with an excellent record of patient safety and reliable results, currently dominates U.S. aesthetics sales, remaining strong even throughout the recent economic downturn. The imminent emergence of their first U.S. rival; however, coupled with news of the FDA's stern ruling that Botox(R) must have stronger product safety warnings might be giving Allergan some cause for concern.

Physician injectors who have worked with both Botox(R) and Dysport(TM) have reported that while the two are relatively comparable, they sometimes prefer one over the other in certain facial areas, due to differences in the onset of results, and spread of effect. Dysport(TM) is decidedly faster-acting and has a greater 'spread' (giving a more 'natural' look); while Botox(R) tends to remain more localized, allowing for greater precision and predictability in the treatment area, but possibly requiring more injections in the course of a treatment.

Jeffrey Adelglass, M.D., F.A.C.S., a cosmetic physician and Medical Director of SKINTASTIC Medical and Surgical Rejuvenation Center of Plano, who is currently one of the largest injectors of Botox in North Texas and the U.S., says, "the major benefits of Dysport(TM) to the cosmetic patient will be that there are fewer injections, and treatments hopefully will last a little longer". However, Dr. Adelglass also stresses that knowing your cosmetic injector has the right credentials and training will be very important. "It is suggested that Dysport(TM) results might last up to a month or even two beyond that of Botox(R) -- which could be a real bonus as long as the outcome is what you wanted; if not, you'll have that much longer to live with the results."

Experience counts. Jeffrey Adelglass, M.D., F.A.C.S. serves on the medical advisory board for Dysport(TM), and on the National Education Foundation for Allergan, instructing other cosmetic physicians to safely administer Botox(R) Cosmetic using his well-honed injection techniques. He was the first Texas physician to achieve simultaneous Diamond pinnacle-level status as a Botox(R) injector and Triple-Platinum status with Medicis, the makers of Restylane(R) and Perlane(R) injectable fillers. Dr. Adelglass is also an exclusive Black Card member of Radiesse(R) physician injectors. He serves on the scientific advisory boards or educational council of most, if not all U.S. dermal filler companies, Dr. Adelglass is also an official training instructor for SmartLipo(TM) MPX laser body sculpting, the DOT Fractional skin resurfacing laser, and ArteFill(R) permanent dermal filler. With his level of experience, it's no wonder that many of the representatives of these companies, with all their available options, select Dr. Adelglass as their own cosmetic physician of choice.

Call (972) 620-3223 to be added to a waiting list to receive a complimentary Dysport(TM) evaluation (and to receive a special introductory offer).Dysport(TM)-related questions can also be directed to Dr. Adelglass at skintastic@skintastic.com. Skintastic is located in the Presbyterian Plano Center for Diagnostics and Surgery at 6020 W. Parker, Suite 400 in Plano, Texas.


'/>"/>
SOURCE Jeffrey Adelglass, M.D., F.A.C.S.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. American Society for Dermatologic Surgery Supports Current Labeling of Allergans Botox(R) Products
2. AAFPRS Speaks to the Safety of BOTOX(R) Cosmetic
3. GFX: Wrinkle-Killer or Botox(R) Hit-Man?
4. Botox(R) vs. Reloxin(R) -- the Wrinkle Titans Poised for Battle
5. Data from Patient Subsets of e-HEALING, a Worldwide Registry, Support Use of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) as Alternative to Drug- Eluting Stents
6. FDA Seeks to Regulate Complementary and Alternative Medicine; Products Such as Vegetable Juice Could Be Restricted for Medical Use
7. GladRags Introduces the Moon Cup - An Environmentally-Sound and Safe Alternative to Disposable Feminine Hygiene Products!
8. Trade-offs reveal no clear favorites in alternative energy market
9. Clinical trials present better alternatives for dialysis patients
10. New Technology at Unitrin Direct Gives Customers an Alternative to Waiting
11. Stem cells in adult testes provide alternative to embryonic stem cells for organ regeneration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... ... with the Home Care Association of America (HCAOA). This agreement allows HCAOA members ... services, as well as discounts on Accreditation University (AU) educational resources that help ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... to announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to ... since it streamlines the reporting process and provides a familiar interface that does ...
(Date:4/28/2017)... ... 2017 , ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced ... its outlook as “stable.” At the same time, the ratings agency cautioned that the ... dip below “capital adequacy” thresholds required for its strong rating. , “Horizon is committed ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, Inc. announced today ... throughout the Northeast U.S. , GlycoMark is the only clinically available blood ... provides a clinically proven one- to two-week measure of hyperglycemic excursions, often related ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America ... lamps offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start ... ballasts. These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor ...
Breaking Medicine News(10 mins):
(Date:4/24/2017)... 2017 Solentim, the developer of instrumentation ... of a major new product line called the ... VIPS has been developed for automatically seeding single ... part of the process to generate clonally-derived cell ... more reliable solution when compared to traditional single ...
(Date:4/20/2017)... , April 20, 2017 ... "Global Biosimilar Pipeline and Market Prospects: Addressing Production ... report to their offering. ... "Global Biosimilar Pipeline and Market Prospects: ... Design" provides an in-depth assessment of the current trends ...
(Date:4/20/2017)... April 20, 2017  AbbVie (NYSE: ABBV), a ... (n=145/146) of chronic hepatitis C virus (HCV) infected ... 6 and compensated cirrhosis (Child-Pugh A) achieved sustained ... ) with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir ... seen following 12 weeks of G/P treatment without ...
Breaking Medicine Technology: